These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 28736525)

  • 21. Impact, Characterization, and Rescue of Pre-mRNA Splicing Mutations in Lysosomal Storage Disorders.
    Dardis A; Buratti E
    Genes (Basel); 2018 Feb; 9(2):. PubMed ID: 29415500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders.
    Pastores GM; Sathe S
    Drugs R D; 2006; 7(6):339-48. PubMed ID: 17073517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis.
    Mu TW; Fowler DM; Kelly JW
    PLoS Biol; 2008 Feb; 6(2):e26. PubMed ID: 18254660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders.
    Rappaport J; Manthe RL; Solomon M; Garnacho C; Muro S
    Mol Pharm; 2016 Feb; 13(2):357-368. PubMed ID: 26702793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological chaperones as therapeutics for lysosomal storage diseases.
    Boyd RE; Lee G; Rybczynski P; Benjamin ER; Khanna R; Wustman BA; Valenzano KJ
    J Med Chem; 2013 Apr; 56(7):2705-25. PubMed ID: 23363020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent developments in therapeutic approaches for lysosomal storage diseases.
    Urbanelli L; Magini A; Polchi A; Polidoro M; Emiliani C
    Recent Pat CNS Drug Discov; 2011 Jan; 6(1):1-19. PubMed ID: 21073432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic approaches for lysosomal storage diseases: a patent update.
    Urbanelli L; Sagini K; Polidoro M; Brozzi A; Magini A; Emiliani C
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):91-109. PubMed ID: 23713988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases.
    Oh DB
    BMB Rep; 2015 Aug; 48(8):438-44. PubMed ID: 25999178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia.
    Puentes-Tellez MA; Lerma-Barbosa PA; Garzón-Jaramillo RG; Suarez DA; Espejo-Mojica AJ; Guevara JM; Echeverri OY; Solano-Galarza D; Uribe-Ardila A; Alméciga-Díaz CJ
    Heliyon; 2020 Mar; 6(3):e03635. PubMed ID: 32258481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.
    Haneef SA; Doss CG
    Adv Protein Chem Struct Biol; 2016; 102():225-65. PubMed ID: 26827607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From bedside to cell biology: a century of history on lysosomal dysfunction.
    Coutinho MF; Matos L; Alves S
    Gene; 2015 Jan; 555(1):50-8. PubMed ID: 25275857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update on gene therapy for lysosomal storage disorders.
    Nagree MS; Scalia S; McKillop WM; Medin JA
    Expert Opin Biol Ther; 2019 Jul; 19(7):655-670. PubMed ID: 31056978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological Chaperones: Beyond Conformational Disorders.
    Leidenheimer NJ
    Handb Exp Pharmacol; 2018; 245():135-153. PubMed ID: 29071508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GCase Enhancers: A Potential Therapeutic Option for Gaucher Disease and Other Neurological Disorders.
    Martínez-Bailén M; Clemente F; Matassini C; Cardona F
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Trials for Gene Therapy in Lysosomal Diseases With CNS Involvement.
    Sevin C; Deiva K
    Front Mol Biosci; 2021; 8():624988. PubMed ID: 34604300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defective collagen proteostasis and matrix formation in the pathogenesis of lysosomal storage disorders.
    Settembre C; Cinque L; Bartolomeo R; Di Malta C; De Leonibus C; Forrester A
    Matrix Biol; 2018 Oct; 71-72():283-293. PubMed ID: 29870768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and Future Treatments for Lysosomal Storage Disorders.
    Rastall DPW; Amalfitano A
    Curr Treat Options Neurol; 2017 Nov; 19(12):45. PubMed ID: 29101575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.
    Biffi A
    Mol Ther; 2017 May; 25(5):1155-1162. PubMed ID: 28389320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy for lysosomal storage diseases: progress, challenges and future prospects.
    Seregin SS; Amalfitano A
    Curr Pharm Des; 2011; 17(24):2558-74. PubMed ID: 21774776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematopoietic stem cell transplant for lysosomal storage diseases.
    Lund TC
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():91-8. PubMed ID: 24380127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.